// App-Quantinova.ai

: Dupilumab efficacy in patients with GINA-defined type 2 asthma: TRAVERSE

Researchers

Presenter

  • Eric D. Bateman

Principal Investigators

  • Ian D. Pavord

  • William W. Busse

  • Nadia Daizadeh

  • Yamo Deniz

  • Paul Rowe

  • Juby A. Jacob-Nara

  • Rebecca Gall

  • Nami Pandit-Abid

  • Benjamin Ortiz

Medical Centers

  • Sanofi US, Bridgewater, United States of America

  • Sanofi US, Bridgewater, United States of America

  • Regeneron Pharmaceuticals - Tarrytown - United States of America

  • University of Cape Town Lung Institute & University of Cape Town, Cape Town, South Africa

  • NIHR Oxford Biomedical Research Centre, Oxford University, Oxford, United Kingdom.

  • UW Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, United States of America

Locations

  • United States

  • South Africa

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • Immunoglobulin E

Drug/Treatment

  • Dupilumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • NCT02414854

  • NCT02134028

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved